Media stories about Prothena Corporation PLC (NASDAQ:PRTA) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Prothena Corporation PLC earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.9400159484885 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Prothena Corporation PLC (NASDAQ:PRTA) opened at 61.24 on Monday. Prothena Corporation PLC has a one year low of $40.58 and a one year high of $69.53. The company’s 50-day moving average price is $59.86 and its 200 day moving average price is $55.95. The firm’s market capitalization is $2.34 billion.
Prothena Corporation PLC (NASDAQ:PRTA) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.43. The firm had revenue of $26.81 million during the quarter, compared to analyst estimates of $16.08 million. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The firm’s quarterly revenue was up 7951.1% on a year-over-year basis. During the same period last year, the company posted ($1.18) EPS. On average, analysts forecast that Prothena Corporation PLC will post ($4.52) earnings per share for the current year.
PRTA has been the subject of several recent analyst reports. Zacks Investment Research raised Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a report on Friday, August 11th. BidaskClub cut Prothena Corporation PLC from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Jefferies Group LLC initiated coverage on Prothena Corporation PLC in a report on Monday, July 10th. They issued a “buy” rating and a $100.00 price target for the company. BTIG Research initiated coverage on Prothena Corporation PLC in a report on Friday, May 19th. They issued a “buy” rating and a $80.00 price target for the company. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Prothena Corporation PLC in a report on Tuesday, May 16th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $77.58.
TRADEMARK VIOLATION NOTICE: “Prothena Corporation PLC (PRTA) Earning Somewhat Positive Media Coverage, Report Shows” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://sportsperspectives.com/2017/09/11/prothena-corporation-plc-prta-earning-somewhat-positive-media-coverage-report-shows.html.
In other Prothena Corporation PLC news, Director Dennis J. Selkoe sold 3,500 shares of the stock in a transaction on Friday, July 7th. The stock was sold at an average price of $58.11, for a total transaction of $203,385.00. Following the completion of the transaction, the director now directly owns 6,345 shares of the company’s stock, valued at approximately $368,707.95. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Karin L. Walker sold 5,000 shares of the stock in a transaction on Monday, July 17th. The shares were sold at an average price of $64.89, for a total value of $324,450.00. Following the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at $324,450. The disclosure for this sale can be found here. Company insiders own 3.10% of the company’s stock.
About Prothena Corporation PLC
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.